Adverse event notifications implicating metformin with lactic acidosis in Australia-Reference-Cited by-同舟云学术

Adverse event notifications implicating metformin with lactic acidosis in Australia

Published:2015-11 Issue:8 Volume:29 Page:1261-1265
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Huang Weiyi,Castelino Ronald L.,Peterson Gregory M.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference43 articles.

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group;Lancet,1998

2. Type 2 Diabetes: The management of type 2 diabetes (NICE clinical guideline 87). National Institute for Health and Care Excellence [updated July 2014]; 2009. Available at: https://www.nice.org.uk/guidance/cg87. (accessed 21 October 2014).

3. The pharmaceutical benefits scheme;Australian Statistics on Medicines,1997

4. Metformin;Bailey;New England Journal of Medicine,1996

5. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested case–control analysis;Bodmer;Diabetes Care,2008

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preadmission metformin use increased the incidence of hyperlactatemia at admission and 30-day in-hospital mortality among T2D patients with heart disease at high risk of hypoxia;International Journal of Cardiology;2024-10

2. Metformin exposure and the incidence of lactic acidosis in critically ill patients with T2DM: A retrospective cohort study;Science Progress;2024-07

3. The determination of the effect(s) of solute carrier family 22-member 2 (SLC22A2) haplotype variants on drug binding via molecular dynamic simulation systems;Scientific Reports;2022-10-08

4. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response;PLOS ONE;2022-07-29

5. Promoter haplotype structure of solute carrier 22 member 2 (SLC22A2) in the Xhosa population of South Africa and their differential effect on gene expression;Gene;2022-04